高级检索
当前位置: 首页 > 详情页

Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China [2]Department of Clinical Pharmacology, PLA General Hospital, Beijing 100853, China [3]State Key Laboratory of Respiratory Diseases, theFirst Affiliated Hospital of Guangzhou Medical College, Guangzhou 510000, China [4]Department of Laboratory Medicine, Peking UniversityPeople’s Hospital, Beijing 100044, China [5]Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China [6]Department ofRespiratory Medicine, the First Affiliated Hospital of Sun Yat-sen University, Institute of Respiratory Diseases of Sun Yat-sen University, Guangzhou510080, China [7]Department of Respiratory Diseases, PLA General Hospital, Beijing 100853, China [8]Department of Respiratory and Critical CareMedicine, the Affiliated Hospital of the Academy of Military Medical Science, Beijing 100071, China [9]Department of Respiratory and Critical CareMedicine, China-Japan Friendship Hospital, Beijing 100029, China
出处:
ISSN:

关键词: Mycoplasma pneumoniae (MP) fluoroquinolones antibiotic resistance beta-lactams point mutation

摘要:
Background: Drug resistant Mycoplasma pneumoniae (MP) is a rising issue in the management of community-acquired pneumonia (CAP). Epidemiological monitoring is essential for identifying resistant patterns of MP isolates against various antibiotics in adult CAP patients. Methods: This is a prospectively designed multicenter study conducted on adult patients with CAP visiting six teaching hospitals in the cities of Beijing, Shanghai and Guangzhou between September 2010 and June 2012. Results: A total of 520 adult patients (mean age: 45.7 +/- 26.2 years) with CAP visiting teaching hospitals in the cities of Beijing, Shanghai and Guangzhou were included. Of the 520 patients, only 75 (14.42%) were confirmed MP positive by means of culture and real-time PCR methods. Quinolones were the most common initially prescribed antimicrobial, followed by beta-lactams and beta-lactams plus quinolones. Macrolide resistance was as high as 80% and 72% against erythromycin (ERY) and azithromycin (AZM) respectively, which were associated with the A2063G transition mutation in domain V of the 23S ribosomal RNA (rRNA) gene. Six strains with mild to moderate ERY-resistant level were still susceptible to AZM. Tetracycline (TET), minocycline (MIN) and quinolones [moxifloxacin (MOX) and fluoroquinolones] had no signs of resistance. Conclusions: High resistance was observed with macrolides, whereas, none of the MP strains were resistant to fluoroquinolones and TET. Hence, macrolide resistant MP (MRMP)_infections could be well treated with fluoroquinolones. However, few isolated strains had minimal inhibitory concentration (MIC) values on the edge of resistance to quinolones, alarming a quinolone-resistant MP in the near future.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 呼吸系统
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 呼吸系统
JCR分区:
出版当年[2015]版:
Q3 RESPIRATORY SYSTEM
最新[2023]版:
Q3 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2015版] 出版当年五年平均[2011-2015] 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者单位: [1]Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
通讯作者:
通讯机构: [7]Department of Respiratory Diseases, PLA General Hospital, Beijing 100853, China [9]Department of Respiratory and Critical CareMedicine, China-Japan Friendship Hospital, Beijing 100029, China [*1]Department of Respiratory Diseases, PLA General Hospital, Beijing 100853, China [*2]Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)